GLP1R and metabolic dysfunction-associated steatotic liver disease: (BMI) Body mass index, (DDP-4I) Dipeptidyl peptidase-4 inhibitors, (GLP-1 RA) Glucagon-like peptide-1 receptor agonist, (HOMA-IR) homeostasis model assessment of insulin resistance, (NAFLD) nonalcoholic fatty liver disease, (M) Men and (W) Women, (US) liver ultrasound.